G1 Therapeutics, Inc. (GTHX)
GTHX moved a median of +0.21% 30 minutes after news, and +0.57% by the close. How GTHX actually reacts to news — the realized, point-in-time move the market made, measured across 142 labeled events over the last three years with zero look-ahead.
GTHX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.11% | 57% | 116 |
| 30-min | +0.21% | 66% | 116 |
| 60-min | +0.18% | 58% | 116 |
| to close | +0.57% | 58% | 116 |
| Middle 50% of GTHX reactions | -0.07% to +4.38% |
|---|---|
| Median reaction (30-min) | +0.21% |
| Measured reactions | 142 |
Half of all G1 Therapeutics, Inc. news events land between -0.07% and +4.38% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How GTHX reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst downgrades | 11 | +0.21% | 100% | 0.00% |
| Rating reiterations | 32 | +0.11% | 50% | +1.32% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how GTHX ranks against every other measured name →
That’s how GTHX usually reacts — get an email when it moves on news →Email me when GTHX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to GTHX's baseline. Nothing else.
Recent GTHX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 15-12G G1 Therapeutics, Inc. | SEC filing · Form 15-12G | SEC EDGAR | — | — | |
| Form 8-K G1 Therapeutics, Inc. For: Sep 18 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form S-8 POS G1 Therapeutics, Inc. | SEC filing · Form S-8 | SEC EDGAR | — | — | |
| Pharmacosmos Group and G1 Therapeutics Announce Successful Closing of Tender Offer | Press release | GlobeNewswire | — | — | |
| Pharmacosmos Group and G1 Therapeutics Announce Expiration of Hart-Scott-Rodino Waiting Period | Press release | GlobeNewswire | +0.00% | +0.00% | |
| Form 10-Q G1 Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.07% | +0.14% | |
| Form 8-K G1 Therapeutics, Inc. For: Aug 08 | SEC filing · Form 8-K | SEC EDGAR | +0.25% | +0.57% | |
| G1 Therapeutics Provides Second Quarter 2024 Financial Results and Operational Highlights | Press release | GlobeNewswire | +0.25% | +0.57% | |
| Form 8-K G1 Therapeutics, Inc. For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | -0.21% | -0.28% | |
| GTHX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of G1 Therapeutics, Inc. Is Fair to Shareholders | Press release | Business Wire | -0.21% | -0.28% | |
| Pharmacosmos Group to Acquire G1 Therapeutics | Press release | GlobeNewswire | -0.21% | -0.28% | |
| G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.75% | -0.75% | |
| G1 Therapeutics to Release Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024 | Press release | GlobeNewswire | +0.27% | +4.78% | |
| G1 Therapeutics Added to the Russell 2000® and 3000® Indexes | Press release | GlobeNewswire | -3.40% | +5.11% | |
| Form 8-K G1 Therapeutics, Inc. For: Jun 24 | SEC filing · Form 8-K | SEC EDGAR | +12.33% | +52.05% | |
| G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer (mTNBC) | Press release | GlobeNewswire | +12.33% | +52.05% | |
| Form 8-K G1 Therapeutics, Inc. For: Jun 13 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -4.30% | |
| G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.94% | +0.00% | |
| Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC) | Press release | GlobeNewswire | -2.56% | -16.26% | |
| G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) Meeting | Press release | GlobeNewswire | -1.86% | -4.66% | |
| G1 Therapeutics and Deimos Biosciences Announce Global (Excluding Asia-Pacific) License Agreement for Lerociclib for Radioprotective Uses | Press release | GlobeNewswire | -0.43% | -6.30% | |
| G1 Therapeutics to Participate in TD Cowen’s 5th Annual Oncology Innovation Summit | Press release | GlobeNewswire | -1.74% | -6.30% | |
| Form 10-Q G1 Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +2.65% | +6.99% | |
| Form 8-K G1 Therapeutics, Inc. For: May 01 | SEC filing · Form 8-K | SEC EDGAR | +5.68% | +17.33% | |
| G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib | Press release | GlobeNewswire | +5.68% | +17.33% | |
| G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +2.65% | +6.99% | |
| G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights | Press release | GlobeNewswire | +5.68% | +17.33% | |
| Form ARS G1 Therapeutics, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.91% | +3.64% | |
| Form DEF 14A G1 Therapeutics, Inc. For: Jun 13 | SEC filing · Form DEF | SEC EDGAR | +0.91% | +3.64% | |
| Form DEFA14A G1 Therapeutics, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +0.91% | +3.64% | |
| G1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024 | Press release | GlobeNewswire | +1.93% | +3.13% | |
| Form PRE 14A G1 Therapeutics, Inc. For: Jun 13 | SEC filing · Form PRE | SEC EDGAR | -1.74% | -6.51% | |
| G1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference | Press release | GlobeNewswire | +0.22% | -0.65% | |
| G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -2.56% | +2.45% | |
| Form 8-K G1 Therapeutics, Inc. For: Mar 21 | SEC filing · Form 8-K | SEC EDGAR | +1.51% | +4.54% | |
| G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -6.49% | -4.93% | |
| Form 10-K G1 Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +2.50% | +3.75% | |
| Form 8-K G1 Therapeutics, Inc. For: Feb 28 | SEC filing · Form 8-K | SEC EDGAR | +5.75% | +32.14% | |
| G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights | Press release | GlobeNewswire | +5.75% | +32.14% | |
| G1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference | Press release | GlobeNewswire | +0.85% | +1.70% | |
| G1 Therapeutics to Release Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on February 28, 2024 | Press release | GlobeNewswire | +4.90% | +0.00% | |
| Form 8-K G1 Therapeutics, Inc. For: Feb 12 | SEC filing · Form 8-K | SEC EDGAR | -4.22% | -15.66% | |
| G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee | Press release | GlobeNewswire | -4.22% | -15.66% | |
| Form 8-K G1 Therapeutics, Inc. For: Jan 08 | SEC filing · Form 8-K | SEC EDGAR | +8.07% | +16.27% | |
| G1 Therapeutics Provides Corporate Update at the 42nd Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | +8.07% | +16.27% | |
| G1 Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | -1.14% | -2.94% | |
| G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -1.14% | -2.94% | |
| G1 Therapeutics Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent Anticancer Therapy | Press release | GlobeNewswire | -2.48% | -8.91% | |
| G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +3.50% | +0.00% | |
| G1 Therapeutics Announces Upcoming Presentation at the 2023 San Antonio Breast Cancer Symposium | Press release | GlobeNewswire | +0.58% | +8.67% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the GTHX section they belong to.
Where else GTHX is measured.
GTHX earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Redhill Biopharma Ltd. - American Depositary Shares (RDHL) | 143 | -0.50% | 39% |
| Alimera Sciences, Inc. (ALIM) | 142 | 0.00% | 42% |
| InflaRx N.V. (IFRX) | 142 | 0.00% | 48% |
| Oncocyte Corporation (OCX) | 141 | 0.00% | 47% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is G1 Therapeutics, Inc.'s median reaction calculated?
Every labeled GTHX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 142 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 66% of GTHX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does GTHX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.